344 related articles for article (PubMed ID: 32778601)
1. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses.
Schandelmaier S; Briel M; Varadhan R; Schmid CH; Devasenapathy N; Hayward RA; Gagnier J; Borenstein M; van der Heijden GJMG; Dahabreh IJ; Sun X; Sauerbrei W; Walsh M; Ioannidis JPA; Thabane L; Guyatt GH
CMAJ; 2020 Aug; 192(32):E901-E906. PubMed ID: 32778601
[TBL] [Abstract][Full Text] [Related]
2. A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analyses.
Schandelmaier S; Chang Y; Devasenapathy N; Devji T; Kwong JSW; Colunga Lozano LE; Lee Y; Agarwal A; Bhatnagar N; Ewald H; Zhang Y; Sun X; Thabane L; Walsh M; Briel M; Guyatt GH
J Clin Epidemiol; 2019 Sep; 113():159-167. PubMed ID: 31132471
[TBL] [Abstract][Full Text] [Related]
3. Credibility of claims of subgroup effects in randomised controlled trials: systematic review.
Sun X; Briel M; Busse JW; You JJ; Akl EA; Mejza F; Bala MM; Bassler D; Mertz D; Diaz-Granados N; Vandvik PO; Malaga G; Srinathan SK; Dahm P; Johnston BC; Alonso-Coello P; Hassouneh B; Walter SD; Heels-Ansdell D; Bhatnagar N; Altman DG; Guyatt GH
BMJ; 2012 Mar; 344():e1553. PubMed ID: 22422832
[TBL] [Abstract][Full Text] [Related]
4. The credibility of subgroup analyses reported in stroke trials is low: A systematic review.
Ademola A; Thabane L; Adekanye J; Okikiolu A; Babatunde S; Almekhlafi MA; Menon BK; Hill MD; Hildebrand KA; Sajobi TT
Int J Stroke; 2023 Dec; 18(10):1161-1168. PubMed ID: 36988330
[TBL] [Abstract][Full Text] [Related]
5. Evidence-based Urology: Subgroup Analysis in Randomized Controlled Trials.
Kilpeläinen TP; Tikkinen KAO; Guyatt GH; Vernooij RWM
Eur Urol Focus; 2021 Nov; 7(6):1237-1239. PubMed ID: 34688589
[TBL] [Abstract][Full Text] [Related]
6. Strategies to improve the credibility of meta-analyses in spine surgery: a systematic survey.
Evaniew N; van der Watt L; Bhandari M; Ghert M; Aleem I; Drew B; Guyatt G
Spine J; 2015 Sep; 15(9):2066-76. PubMed ID: 26002725
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of an instrument for the critical appraisal of randomized controlled trials of natural products.
Jurgens T; Whelan AM; MacDonald M; Lord L
BMC Complement Altern Med; 2009 Apr; 9():11. PubMed ID: 19389240
[TBL] [Abstract][Full Text] [Related]
8. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
Jansen JP; Trikalinos T; Cappelleri JC; Daw J; Andes S; Eldessouki R; Salanti G
Value Health; 2014 Mar; 17(2):157-73. PubMed ID: 24636374
[TBL] [Abstract][Full Text] [Related]
9. A systematic review reveals that the credibility of subgroup claims in low back pain trials was low.
Saragiotto BT; Maher CG; Moseley AM; Yamato TP; Koes BW; Sun X; Hancock MJ
J Clin Epidemiol; 2016 Nov; 79():3-9. PubMed ID: 27297201
[TBL] [Abstract][Full Text] [Related]
10. Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT).
Butcher NJ; Monsour A; Mew EJ; Szatmari P; Pierro A; Kelly LE; Farid-Kapadia M; Chee-A-Tow A; Saeed L; Monga S; Ungar W; Terwee CB; Vohra S; Fergusson D; Askie LM; Williamson PR; Chan AW; Moher D; Offringa M
Trials; 2019 Mar; 20(1):161. PubMed ID: 30841935
[TBL] [Abstract][Full Text] [Related]
11. Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment.
Hammad TA; Neyarapally GA; Pinheiro SP; Iyasu S; Rochester G; Dal Pan G
Clin Trials; 2013; 10(3):389-97. PubMed ID: 23508987
[TBL] [Abstract][Full Text] [Related]
12. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.
Manchikanti L; Datta S; Smith HS; Hirsch JA
Pain Physician; 2009; 12(5):819-50. PubMed ID: 19787009
[TBL] [Abstract][Full Text] [Related]
13. Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials.
Khan MS; Khan MAA; Irfan S; Siddiqi TJ; Greene SJ; Anker SD; Sreenivasan J; Friede T; Tahhan AS; Vaduganathan M; Fonarow GC; Butler J
ESC Heart Fail; 2021 Feb; 8(1):26-36. PubMed ID: 33254286
[TBL] [Abstract][Full Text] [Related]
14. A checklist to evaluate a report of a nonpharmacological trial (CLEAR NPT) was developed using consensus.
Boutron I; Moher D; Tugwell P; Giraudeau B; Poiraudeau S; Nizard R; Ravaud P
J Clin Epidemiol; 2005 Dec; 58(12):1233-40. PubMed ID: 16291467
[TBL] [Abstract][Full Text] [Related]
15. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review.
Zeng X; Zhang Y; Kwong JS; Zhang C; Li S; Sun F; Niu Y; Du L
J Evid Based Med; 2015 Feb; 8(1):2-10. PubMed ID: 25594108
[TBL] [Abstract][Full Text] [Related]
16. Assessing the reporting and scientific quality of meta-analyses of randomized controlled trials of treatments for anxiety disorders.
Bereza BG; Machado M; Einarson TR
Ann Pharmacother; 2008 Oct; 42(10):1402-9. PubMed ID: 18728102
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study.
Devji T; Carrasco-Labra A; Qasim A; Phillips M; Johnston BC; Devasenapathy N; Zeraatkar D; Bhatt M; Jin X; Brignardello-Petersen R; Urquhart O; Foroutan F; Schandelmaier S; Pardo-Hernandez H; Vernooij RW; Huang H; Rizwan Y; Siemieniuk R; Lytvyn L; Patrick DL; Ebrahim S; Furukawa T; Nesrallah G; Schünemann HJ; Bhandari M; Thabane L; Guyatt GH
BMJ; 2020 Jun; 369():m1714. PubMed ID: 32499297
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials.
Wallach JD; Sullivan PG; Trepanowski JF; Sainani KL; Steyerberg EW; Ioannidis JP
JAMA Intern Med; 2017 Apr; 177(4):554-560. PubMed ID: 28192563
[TBL] [Abstract][Full Text] [Related]
19. Impact of the PATH Statement on Analysis and Reporting of Heterogeneity of Treatment Effect in Clinical Trials: A Scoping Review.
Selby JV; Maas CCHM; Fireman BH; Kent DM
medRxiv; 2024 May; ():. PubMed ID: 38766150
[TBL] [Abstract][Full Text] [Related]
20. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations.
Hammad TA; Pinheiro SP; Neyarapally GA
Clin Trials; 2011 Oct; 8(5):559-70. PubMed ID: 21878445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
